Executive Summary

Next Pharma Inc. (NPI) is a biotechnology company focusing on developing and commercializing products for the early detection, diagnosis and monitoring the recurrence of **Cancer and COVID-19**. Next Pharma Inc. has developed a blood test using a novel cancer biomarker which is over expressed in cancer cells.

Early diagnosis and treatment of cancer can play a key role in increasing patient's chances of survival. However, current cancer diagnostic modalities are still not accurate, may take up to several months to obtain results and the associated costs are extremely high. NPI offers patients with **highly accurate, reliable, fast and cost-effective blood tests,** which can be used for early diagnosis, remission and recurrence of cancer following the treatment.
NPI is currently at the stage of manufacturing and launching its diagnostic test which can be used for the early detection of 27 different cancers including Breast, Colon, Prostate, Pancreas, Thyroid, Gastric, and Lung Cancers, which make up over 98% of cases of cancer in North America. The technology is protected by patent applications worldwide. Next Pharma Inc. Blood Test is provided in a kit of reagents to laboratories that have been fully trained and a comprehensive technological transfer has been completed. The technology will be offered in an automated format using ELISA automation machines that is being customized to perform the Next Pharma Inc. Standard Operating Procedure (SOP).

Collaborations: Research and manufacturing done both at the Company and in collaboration with National and International Universities including, *Department of Animal Sciences, Pharmaceutical Research Center, Research and Technology Center of Bio-molecules Department of Medical Immunology and Hematology*.

NPI is headquartered in Toronto, Ontario, Canada and will globally distribute and commercialize its diagnostic tests. NPI's diagnostic tests are regarded as revolutionary as they can help to diagnose cancer at an **early stage** using a blood serum with **high sensitivity/high specificity**, **fast turnaround** (within 4 hours), are relatively **inexpensive** and are **non-invasive**. NPI's current product line will be operating in the "new generation diagnostics market" projected to be valued at over $5 billion by 2022. Projected net revenues to NPI in 2022 are expected to be **above $640 millions**. **Indeed, we have 25 costumers (for 25 different countries) which are willing to buy three million laboratory tests supported by LC (Letter of Credit), post manufacturing.**

NPI's corporate development strategy involves the development and sustainment of regional partnerships through exclusive licensing agreements. NPI will supply each regional partner with the ELISA format "AABH kits" and the rights to perform the diagnostic tests in their regions based on its Standard Operating Procedures (SOPs). The regional partners will be selected based on necessary prerequisites, will have their Central Medical Laboratories, certified technicians trained, and evaluated and monitored marketing plans. NPI's source of revenue will be on a per unit basis from each regional partner for the use of the technology and test reagents.

Next Pharma AABH ELISA Test, is a Laboratory Developed Test (LDT), manufactured in CLIA* certified Laboratory and ISO 13485 Certified Lab. At this point, Next Pharma is in the process of manufacturing, commercialization and marketing in 25 different countries through its designated exclusive local partners. The commercial partners are trained to perform the Next Pharma Blood Test in their local certified laboratories.

* The Clinical Laboratory Improvement Amendments (CLIA) of 1988 are United States federal regulatory standards that apply to all clinical laboratory testing performed on humans.
* ISO 13485 is an internationally recognized quality standard which states the requirements of the Quality Management System (QMS) for the design and manufacture of Medical Devices (Laboratory Blood Tests) throughout the world.

175 Commerce Valley Drive West, Suite 350, Markham, Ontario, L3T 7P6, **Canada.**
Phone: +416-450-6414 Fax: +905-237-5557 www.nextpharmainc.com